Skip to content

Insider · CIK 0001856094

Blake Borgeson

director

Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Oct 17, 2024, latest Oct 7, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 6
$0 bought, $1.5M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

RXRX: RECURSION PHARMACEUTICALS, INC.

RXRXOct 9, 2026 · close 4.36

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
16Weak
RXRXsell 210b5-1
RECURSION PHARMACEUTICALS, INC.
$242k
50,000 shares
-1%+63% from low-32% from high
13Weak
RXRXsell 210b5-1
RECURSION PHARMACEUTICALS, INC.
$100k
30,000 shares
-0%-
19Weak
RXRXsell10b5-1
RECURSION PHARMACEUTICALS, INC.
$961k
220,000 shares
-3%+12% from low-60% from high
19Weak
RXRXsell 310b5-1
RECURSION PHARMACEUTICALS, INC.
$87k
11,447 shares
-0%-
18Weak
RXRXsell 310b5-1
RECURSION PHARMACEUTICALS, INC.
$77k
11,447 shares
-0%-
11Weak
RXRXsell 210b5-1
RECURSION PHARMACEUTICALS, INC.
$76k
11,447 shares
-0%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-50,000$4.84$242k6,108,2875 d ago
Sep 1, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-30,000$3.34$100k6,158,28740 d ago
Dec 2, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-220,000$4.37$961k6,869,863Dec 4, 2025
Jun 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
AGrant or award
Class A Common Stock
+22,016$0.00$07,089,863Jun 23, 2025
Jun 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
AGrant or award
Stock Option (Right to Buy)derivative
+44,031$0.00$044,031Jun 23, 2025
Jan 2, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
AGrant or award
Class A Common Stock
+1,734$0.00$07,067,847Jan 6, 2025
Nov 12, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-11,447$7.64$87k7,066,113Nov 14, 2024
Oct 29, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-11,447$6.72$77k7,077,560Oct 31, 2024
Oct 15, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
SOpen-market sale
Class A Common Stock10b5-1
-11,447$6.67$76k7,089,007Oct 17, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.